AR007479A1 - Un compuesto derivado del 3,5-difenil-1,2,4-triazol sustituido, su uso, un procedimiento para prepararlo y una preparacion farmaceutica que lo comprende. - Google Patents

Un compuesto derivado del 3,5-difenil-1,2,4-triazol sustituido, su uso, un procedimiento para prepararlo y una preparacion farmaceutica que lo comprende.

Info

Publication number
AR007479A1
AR007479A1 ARP970102792A ARP970102792A AR007479A1 AR 007479 A1 AR007479 A1 AR 007479A1 AR P970102792 A ARP970102792 A AR P970102792A AR P970102792 A ARP970102792 A AR P970102792A AR 007479 A1 AR007479 A1 AR 007479A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
substituted
hydroxy
hydrogen
alkyl
Prior art date
Application number
ARP970102792A
Other languages
English (en)
Spanish (es)
Original Assignee
Angelo Noel D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4214048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR007479(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Angelo Noel D filed Critical Angelo Noel D
Publication of AR007479A1 publication Critical patent/AR007479A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP970102792A 1996-06-25 1997-06-25 Un compuesto derivado del 3,5-difenil-1,2,4-triazol sustituido, su uso, un procedimiento para prepararlo y una preparacion farmaceutica que lo comprende. AR007479A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH159396 1996-06-25

Publications (1)

Publication Number Publication Date
AR007479A1 true AR007479A1 (es) 1999-10-27

Family

ID=4214048

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102792A AR007479A1 (es) 1996-06-25 1997-06-25 Un compuesto derivado del 3,5-difenil-1,2,4-triazol sustituido, su uso, un procedimiento para prepararlo y una preparacion farmaceutica que lo comprende.

Country Status (36)

Country Link
US (3) US6465504B1 (forum.php)
EP (1) EP0914118B1 (forum.php)
JP (1) JP3541042B2 (forum.php)
KR (1) KR100616378B1 (forum.php)
CN (1) CN1146415C (forum.php)
AP (1) AP1127A (forum.php)
AR (1) AR007479A1 (forum.php)
AT (1) ATE226435T1 (forum.php)
AU (1) AU718037B2 (forum.php)
BG (1) BG64248B1 (forum.php)
BR (1) BR9709973A (forum.php)
CA (1) CA2255951C (forum.php)
CY (2) CY2429B1 (forum.php)
CZ (1) CZ291470B6 (forum.php)
DE (3) DE69716602T2 (forum.php)
DK (1) DK0914118T3 (forum.php)
ES (1) ES2187785T3 (forum.php)
FR (1) FR06C0049I2 (forum.php)
GE (1) GEP20084355B (forum.php)
HU (1) HU226232B1 (forum.php)
IL (1) IL127212A0 (forum.php)
LT (1) LTC0914118I2 (forum.php)
LU (1) LU91291I2 (forum.php)
MY (1) MY129541A (forum.php)
NL (1) NL300248I2 (forum.php)
NO (3) NO317180B1 (forum.php)
NZ (1) NZ333308A (forum.php)
OA (1) OA10946A (forum.php)
PL (1) PL194758B1 (forum.php)
PT (1) PT914118E (forum.php)
RU (1) RU2208010C2 (forum.php)
SI (1) SI0914118T1 (forum.php)
SK (1) SK284319B6 (forum.php)
TR (1) TR199802693T2 (forum.php)
TW (1) TW533205B (forum.php)
WO (1) WO1997049395A1 (forum.php)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677487B2 (en) 2001-08-30 2004-01-13 Pharmacia Corporation α-haloenamine reagents
GB0126618D0 (en) 2001-11-06 2002-01-02 Novartis Ag Organic compounds
ES2192494B1 (es) * 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
US20090227647A1 (en) 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
KR20060123739A (ko) * 2003-11-10 2006-12-04 머크 앤드 캄파니 인코포레이티드 나트륨 채널 차단제로서의 치환된 트리아졸
RU2006125741A (ru) * 2003-12-19 2008-01-27 Новартис АГ (CH) Комбинация (а) n-{5-[4-(4-метилпиперазинометил)бензоиламило]-2-метилфенил}-4-(3-пиридил)-2-пиримидинамина и (б) по меньшей мере одного ингибитора гипузинации и ее применение
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
EP1755579A4 (en) * 2004-05-24 2009-06-10 Univ New York METHOD OF TREATING OR PREVENTING PATHOLOGICAL EFFECTS OF ACUTE INCREASES IN HYPERGLYCEMIA AND / OR ACUTE INCREASES OF FREE FATTY ACID FLOWS
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
EP1843771B1 (en) * 2005-01-28 2011-09-21 Novartis AG Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
US20080187510A1 (en) * 2005-02-10 2008-08-07 Camenisch Gian P Methods for Improving Drug Disposition
AU2006252718B2 (en) * 2005-05-31 2010-04-15 Novartis Ag Treatment of liver diseases in which iron plays a role in pathogenesis
CN101291655A (zh) * 2005-10-19 2008-10-22 诺瓦提斯公司 包含地拉罗司(deferasirox)的分散片
EP1945272B1 (en) * 2005-11-01 2013-09-11 Novartis AG Method of scintigraphy
CN101415691B (zh) * 2006-02-03 2011-12-14 大正制药株式会社 三唑衍生物
NZ572299A (en) * 2006-05-09 2010-07-30 Novartis Ag Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof
MX2008014837A (es) 2006-05-23 2008-12-01 Novartis Ag Metodo para el tratamiento de hemocromatosis hereditaria.
CL2007002026A1 (es) * 2006-07-13 2008-06-06 Los Angeles Biomed Res Inst Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.
JP2009545547A (ja) * 2006-08-04 2009-12-24 ノバルティス アクチエンゲゼルシャフト 鉄キレーターを使用した内分泌機能不全の処置
RU2339625C2 (ru) * 2006-11-02 2008-11-27 Российский химико-технологический университет (РХТУ им. Д.И. Менделеева) ЗАМЕЩЕННЫЕ N-[ω-АЗОЛ-1-ИЛ)АЛКИЛ]БЕНЗОЛСУЛЬФАМИДЫ В КАЧЕСТВЕ СРЕДСТВ С АНТИАГРЕГАЦИОННОЙ АКТИВНОСТЬЮ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
EP1927591A1 (en) * 2006-11-29 2008-06-04 Novartis AG Polymorphic Forms of Deferasirox (ICL670)
RU2468015C2 (ru) 2006-11-29 2012-11-27 Новартис Аг Полиморфные формы деферасирокса (icl670a)
US20080262060A1 (en) * 2007-01-29 2008-10-23 Toth Zoltan G Crystalline forms of Deferasirox
MX2009012375A (es) * 2007-05-14 2009-12-01 Novartis Ag Uso de quelante del hierro para el tratamiento del infarto de miocardio.
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
US20090082412A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched deferasirox
US20090142395A1 (en) 2007-11-19 2009-06-04 Uri Zadok Deferasirox pharmaceutical compositions
CZ301873B6 (cs) 2008-01-30 2010-07-14 Farmak, A. S. Zpusob prípravy kyseliny 4-[3,5-bis(2-hydroxyfenyl)-[1,2,4]triazol-1-yl]benzoové
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
US20110097413A1 (en) * 2008-04-21 2011-04-28 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
WO2009147529A1 (en) * 2008-06-02 2009-12-10 Actavis Group Ptc Ehf Substantially pure deferasirox and processes for the preparation thereof
JPWO2010032489A1 (ja) 2008-09-22 2012-02-09 国立大学法人旭川医科大学 鉄キレート剤及びその製造方法、並びに鉄イオンの定量・捕捉方法
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
WO2010092419A1 (en) 2009-02-12 2010-08-19 Assistance Publique - Hopitaux De Paris Combined treatment of multiple sclerosis
RU2011142173A (ru) 2009-03-19 2013-04-27 ЛОС-АНДЖЕЛЕС БАЙОМЕДИКАЛ РИСЕРЧ ИНСТИТЬЮТ ЭТ ХАБОР-ЮСиЭлЭй МЕДИКАЛ СЕНТР Вакцинные композиции и способы лечения мукоромикоза и других грибковых заболеваний
IT1398770B1 (it) * 2009-07-22 2013-03-18 Bellacchio Oligonucleotidi attivabili mediante l'appaiamento con sequenze di acidi nucleici e loro uso
WO2011021218A2 (en) * 2009-08-12 2011-02-24 Msn Laboratories Limited Process for the preparation of 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-benzoic acid and its amine salts
AU2010329487A1 (en) * 2009-12-07 2012-06-14 Mapi Pharma Limited Processes for the preparation of deferasirox, and deferasirox polymorphs
EA201390079A1 (ru) 2010-07-08 2013-09-30 Рациофарм Гмбх Пероральная лекарственная форма деферазирокса
EP2632907B1 (en) * 2010-08-25 2015-10-14 Davuluri, Ramamohan Rao Process for preparing 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one and its use for preparing deferasirox
CA2812505A1 (en) * 2010-10-01 2012-04-05 Cipla Limited Pharmaceutical composition
US9018389B2 (en) 2010-11-24 2015-04-28 Alembic Pharmaceuticals, Ltd. Process for the preparation of Deferasirox
EP2664333B1 (en) 2011-01-14 2016-10-12 Disease Adsorption System Technologies Co., Ltd. Polymeric iron chelating agent
US20140316534A1 (en) 2011-10-14 2014-10-23 Photocure Asa Stent
US20140276107A1 (en) 2011-10-14 2014-09-18 Photocure Asa Photodynamic diagnosis
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) * 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
RU2659034C2 (ru) * 2013-03-06 2018-06-27 Биокон Лимитед Способ получения деферазирокса
SI2964202T1 (sl) * 2013-03-08 2019-02-28 Novartis Ag Peroralne formulacije deferasiroksa
AU2014264421A1 (en) * 2013-05-10 2015-12-03 Cipla Limited Low dose pharmaceutical composition
DE102013217390A1 (de) 2013-09-02 2015-03-05 Henkel Ag & Co. Kgaa Wasch- und Reinigungsmittel mit verbesserter Leistung
CN103454370B (zh) * 2013-09-11 2014-12-24 中美华世通生物医药科技（武汉）有限公司 一种利用hplc测定原料药中苯肼类化合物残留的方法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR20240110004A (ko) 2014-03-14 2024-07-12 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
ES2734675T3 (es) 2014-05-20 2019-12-11 Sanovel Ilac Sanayi Ve Ticaret As Formulación de comprimido dispersable en agua que contiene deferasirox
EP2987482A1 (en) 2014-08-22 2016-02-24 Santa Farma Ilaç Sanayi A.S. Soluble and dispersible pharamaceutical deferasirox formulation
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
KR20160088965A (ko) 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
PE20171448A1 (es) 2015-03-10 2017-10-02 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
CN104817538A (zh) * 2015-03-13 2015-08-05 东南大学 去铁斯诺-他克林金属离子鳌合剂及其药物用途
WO2016167729A1 (en) 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
EP3095443A1 (en) 2015-05-21 2016-11-23 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Pharmaceutical composition comprising deferasirox
WO2016203488A1 (en) * 2015-06-16 2016-12-22 Havaldar Freddy H Preparation of novel deferasirox analogues for antimalarial activity
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
KR101695970B1 (ko) * 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
CN106554770B (zh) * 2015-09-29 2018-10-19 杭州杜易科技有限公司 一种三唑衍生物金属离子荧光探针及其制备方法和应用
CA3002416C (en) 2015-10-23 2023-10-24 Vifor (International) Ag Benzimidazolyl derivatives for use as ferroportin inhibitors
EP4424322A3 (en) 2015-12-17 2025-04-16 Novartis AG Antibody molecules to pd-1 and uses thereof
WO2017158559A1 (en) 2016-03-17 2017-09-21 Lupin Limited Compositions of deferasirox
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018059922A1 (en) 2016-09-30 2018-04-05 Synthon B.V. Pharmaceutical composition comprising deferasirox
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CZ2017255A3 (cs) 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION
EP3489692A1 (de) 2017-11-28 2019-05-29 Siemens Healthcare Diagnostics Products GmbH Prothrombinzeit-reagenz enthaltend einen eisenchelator
TR201722910A2 (tr) 2017-12-29 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasi̇roks i̇çeren suda dağilabi̇len tablet formülasyonlari
KR20190110771A (ko) 2018-03-21 2019-10-01 주식회사 한국팜비오 데페라시록스를 함유하는 소형 분산성 정제
CN108727287B (zh) * 2018-05-10 2020-10-27 东南大学 1,2,4-三唑类化合物及其盐和应用
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
GR1009592B (el) * 2018-07-03 2019-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν χηλικο παραγοντα συμπλεκτικο του σιδηρου και μεθοδος για την παρασκευη αυτου
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
IT202000000922A1 (it) 2020-01-20 2021-07-20 Cage Chemicals S R L Complessi di ferro e relativi sali come agenti di contrasto per MRI
US11155547B1 (en) * 2020-06-18 2021-10-26 Alterity Therapeutics Limited Compounds for and methods of treating diseases
EP4052698A1 (en) 2021-03-05 2022-09-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Film coated tablet comprising deferasirox
CN114276305B (zh) * 2021-12-28 2023-11-17 中山大学 一种三取代苯基-1,2,4-三氮唑衍生物及其制备和治疗神经元损伤的应用
CN114478410B (zh) * 2022-03-31 2022-11-29 中山大学 一种二取代苯基-1,2,4-三氮唑衍生物及其制备和应用
CN114591254B (zh) * 2022-03-31 2023-10-13 中山大学 一种3,5-二取代苯基-1,2,4-三氮唑衍生物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH84663A4 (forum.php) 1963-01-24 1964-11-14
DE2628152C2 (de) 1976-06-23 1985-03-28 Bayer Ag, 5090 Leverkusen Fungizide und nematizide Mittel
US4528196A (en) * 1981-02-23 1985-07-09 The United States Of America As Represented By The Department Of Health And Human Services Chelating agents for the treatment of iron overload
SU1280851A1 (ru) * 1983-07-08 1996-05-27 Ростовский государственный университет 1-фенил-3-алкил-5-(o-оксифенил)-1,2,4-триазолы, обладающие транквилизирующим и антигипоксическим действием, и 1-фенил-3-н-бутил-5-(о-оксифенил)-1,2,4-триазол, обладающий транквилизирующим, антигипоксическим и анальгетическим действием
GB8429307D0 (en) 1984-11-20 1984-12-27 Shell Int Research Heterocyclic herbicides
IL84331A0 (en) * 1987-11-02 1988-04-29 Yissum Res Dev Co Pyridoxyl hydrazone derivatives and pharmaceutical compositions containing the same
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel

Also Published As

Publication number Publication date
DK0914118T3 (da) 2003-02-24
OA10946A (en) 2003-02-27
NZ333308A (en) 2000-05-26
HK1020530A1 (en) 2000-05-12
CY2007005I1 (el) 2010-07-28
SI0914118T1 (en) 2003-04-30
ES2187785T3 (es) 2003-06-16
SK178598A3 (en) 1999-06-11
RU2208010C2 (ru) 2003-07-10
CN1223579A (zh) 1999-07-21
HUP9903111A3 (en) 2000-06-28
TW533205B (en) 2003-05-21
PT914118E (pt) 2003-02-28
KR100616378B1 (ko) 2006-08-28
LU91291I2 (fr) 2007-01-29
PL330119A1 (en) 1999-04-26
TR199802693T2 (xx) 1999-05-21
SK284319B6 (sk) 2005-01-03
US6596750B2 (en) 2003-07-22
FR06C0049I1 (forum.php) 2007-03-09
US20030203954A1 (en) 2003-10-30
EP0914118A1 (en) 1999-05-12
DE122007000020I1 (de) 2007-05-24
NO2018014I2 (no) 2018-11-19
NO2018014I1 (no) 2018-04-17
NO986024D0 (no) 1998-12-21
NO986024L (no) 1998-12-21
IL127212A0 (en) 1999-09-22
NL300248I1 (nl) 2007-02-01
BG64248B1 (bg) 2004-07-30
GEP20084355B (forum.php) 2008-04-29
PL194758B1 (pl) 2007-07-31
CN1146415C (zh) 2004-04-21
ATE226435T1 (de) 2002-11-15
NO2006017I1 (no) 2006-12-18
FR06C0049I2 (fr) 2007-04-27
MY129541A (en) 2007-04-30
DE69716602T2 (de) 2003-06-26
LU91291I9 (forum.php) 2018-12-27
WO1997049395A1 (en) 1997-12-31
JP2000507601A (ja) 2000-06-20
US20030069273A1 (en) 2003-04-10
EP0914118B1 (en) 2002-10-23
DE69716602D1 (de) 2002-11-28
CY2429B1 (en) 2004-11-12
HUP9903111A2 (hu) 2000-01-28
US6465504B1 (en) 2002-10-15
CA2255951C (en) 2006-10-10
AP9801407A0 (en) 1998-12-31
CY2007005I2 (el) 2018-12-12
NL300248I2 (nl) 2007-03-01
CZ427298A3 (cs) 1999-03-17
CA2255951A1 (en) 1997-12-31
BR9709973A (pt) 1999-08-10
NO317180B1 (no) 2004-09-06
LTPA2007001I1 (lt) 2018-06-25
HU226232B1 (en) 2008-07-28
NO2006017I2 (no) 2011-07-04
DE122007000020I2 (de) 2010-12-30
US6723742B2 (en) 2004-04-20
CZ291470B6 (cs) 2003-03-12
AU3262997A (en) 1998-01-14
BG103003A (en) 1999-09-30
JP3541042B2 (ja) 2004-07-07
LTC0914118I2 (lt) 2018-12-27
AP1127A (en) 2002-12-06
AU718037B2 (en) 2000-04-06
KR20050098029A (ko) 2005-10-10

Similar Documents

Publication Publication Date Title
AR007479A1 (es) Un compuesto derivado del 3,5-difenil-1,2,4-triazol sustituido, su uso, un procedimiento para prepararlo y una preparacion farmaceutica que lo comprende.
RU97100747A (ru) Ингибиторы ферментов
RU2003135482A (ru) Геропротектор на основе гидрированных пиридо(4,3-b) индолов (варианты), фармакологическое средство на его основе и способ его применения
RU2003130058A (ru) Комбинации, включающие антидиарейный агент и эпотилон или производные эпотилона
RU2006127440A (ru) Пиррольные и пиразольные ингибиторы daao
NZ243443A (en) Triazolopyrimidine derivatives, preparation and pharmaceutical compositions thereof
AR005860A1 (es) Compuestos heterociclicos aromaticos, composiciones farmaceuticas y cosmeticas que los contienen, y su utilización.
HUP9801924A2 (hu) Nátrium/hidrogén-csere inhibitorokat és szív- és keringési zavarok kezelésére alkalmas hatóanyagokat tartalmazó gyógyszerkészítmény
ES8707111A1 (es) Procedimiento para obtencion de un preparado farmaceutico para tratamiento terapeutico de enfermedades reumaticas.
SE9903611D0 (sv) Novel compounds III
RU2005133478A (ru) Применение производных карбамазепина для лечения возбуждения у пациентов, страдающих деменцией
ES8201955A1 (es) Un procedimiento de produccion de derivados del acido 2-hi- droxioxanilico
RU2003104017A (ru) Ингибиторы тромбина, содержащие аминоизохинолиновую группу
DE60007548D1 (de) Omega kettenmodifizierte hydroxyeicosatetraensäure derivate verwendbar in der behandlung der "trockenes auge" krankheit
IE790157L (en) Therapeutic agents
RU93019277A (ru) Раствор для защиты и лечения заболеваний и повреждения роговицы "визитон"
RU99116652A (ru) Способ лечения злокачественной лимфомы кожи
KR920019767A (ko) 티아졸 유도체
KR900000383A (ko) 신규 화합물
RU98114091A (ru) Вещества, связывающие рецепторы гиалуроновой кислоты и их применение
KR890014116A (ko) 고혈압치료 혼합물
RU99109467A (ru) Пуриновые l-нуклеозиды, их аналоги и применение
KR880006236A (ko) 이소퀴놀린 유도체
FR2224152A1 (en) Thiazolotriazolyl phosphorothioates as anthelmintics - combining good anthelmintic activity with low toxicity to warm-blooded animals
EP0717980A2 (en) Use of guanidine-imidazole derivatives to assist hair growth stimulation

Legal Events

Date Code Title Description
FG Grant, registration